{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:42:41Z","timestamp":1790185361289,"version":"4.1.0"},"reference-count":21,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"3","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Rheumatology"],"abstract":"<jats:p>Objectives: This study aimed to examine whether creatine kinase (CK) elevation occurs with interleukin (IL)-6 inhibitors, as in Janus kinase (JAK) inhibitors, which are reported to increase CK levels in rheumatoid arthritis.\r\nPatients and methods: A multicenter database of JAK inhibitor and IL-6 inhibitor treatment was retrospectively searched between January 2016 to December 2022; 142 cases (117 females, 25 males, mean age: 63.8\u00b113.0 years; range, 20 to 85 years), with 71 cases in each group, were extracted by propensity score matching using age, sex, body mass index, and CK at 0 weeks. The outlier rate was compared. Patients\u2019 background characteristics related to elevated CK levels at 24 weeks were investigated by univariate and multivariate analyses.\r\nResults: Creatine kinase levels at 4 and 12 weeks were significantly higher with JAK inhibitors than with IL-6 inhibitors (four weeks, 72 vs. 87.5 IU\/mL, p=0.016; 12 weeks, 71 vs. 95.5 IU\/mL, p=0.028). The outlier rate (Grade 1) with JAK inhibitors increased significantly over time (0 weeks, 4.2%; four weeks, 18.1%; 12 weeks, 21.7%; 24 weeks, 18.3%; p=0.015), whereas that with IL-6 inhibitors increased slightly (0 weeks, 5.6%; four weeks, 9.2%; 12 weeks, 8.6%; 24 weeks, 8.5%; p=0.745), with a significant difference between the groups (p=0.035). No patients discontinued treatment due to myalgia or renal dysfunction. The factors significantly positively related to elevated CK levels at 24 weeks were male sex and creatinine. Those significantly negatively related were Steinbrocker stage and class, modified health assessment questionnaire scores, estimated glomerular filtration rate, and glucocorticoid dose.\r\nConclusion: Mild CK elevations with JAK inhibitors are not a particular clinical problem. CK elevation might be specific to JAK inhibitors.<\/jats:p>","DOI":"10.46497\/archrheumatol.2024.10645","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T08:25:37Z","timestamp":1719908737000},"page":"350-357","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of creatine kinase elevation caused by Janus kinase inhibitors and interleukin-6 inhibitors in patients with rheumatoid arthritis: A propensity score-matched study"],"prefix":"10.5152","volume":"39","author":[{"family":"Masahiro Tada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tadashi Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kenji Mamaoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Yutaro Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kazuki Orita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Koji Mandai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shohei Anno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Takahiro Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kentaro Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tatsuya Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, et al. Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: Final results of a global, open-label, longterm extension study. Arthritis Res Ther 2019;21:89. doi: 10.1186\/s13075-019-1866-2.","DOI":"10.1186\/s13075-019-1866-2"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Takagi M, Atsumi T, Matsuno H, Tamura N, Fujii T, Okamoto N, et al. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Mod Rheumatol 2023;33:647-56. doi: 10.1093\/mr\/roac089.","DOI":"10.1093\/mr\/roac089"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis 2019;78:1305- 19. doi: 10.1136\/annrheumdis-2019-215164.","DOI":"10.1136\/annrheumdis-2019-215164"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial. Ann Rheum Dis 2021;80:848- 58. doi: 10.1136\/annrheumdis-2020-219214.","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: The phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis 2021;80:727-38. doi: 10.1136\/annrheumdis-2020-219213.","DOI":"10.1136\/annrheumdis-2020-219213"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019;71:1788- 800. doi: 10.1002\/art.41032.","DOI":"10.1002\/art.41032"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement. Ann Rheum Dis 2021;80:71-87. doi: 10.1136\/annrheumdis-2020-218398.","DOI":"10.1136\/annrheumdis-2020-218398"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Doles JD, Olwin BB. The impact of JAK-STAT signaling on muscle regeneration. Nat Med 2014;20:1094-5. doi: 10.1038\/nm.3720.","DOI":"10.1038\/nm.3720"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Isaacs JD, Zuckerman A, Krishnaswami S, Nduaka C, Lan S, Hutmacher MM, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: Results from clinical trials. Arthritis Res Ther 2014;16:R158. doi: 10.1186\/ ar4673.","DOI":"10.1186\/ar4673"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Price FD, von Maltzahn J, Bentzinger CF, Dumont NA, Yin H, Chang NC, et al. Inhibition of JAK-STAT signaling stimulates adult satellite cell function. Nat Med 2014;20:1174-81. doi: 10.1038\/nm.3655.","DOI":"10.1038\/nm.3655"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Queeney K, Housley W, Sokolov J, Long A. FRI0131 elucidating the mechanism underlying creatine phosphokinase upregulation with upadacitinib. Ann Rheum Dis 2019;78:734.2-5. doi: 10.1136\/ annrheumdis-2019-eular.7509.","DOI":"10.1136\/annrheumdis-2019-eular.7509"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8. doi: 10.1136\/ard.2010.138461.","DOI":"10.1136\/ard.2010.138461"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, et al. Treating rheumatoid arthritis to target: Multinational recommendations assessment questionnaire. Ann Rheum Dis 2011;70:1999-2002. doi: 10.1136\/ard.2011.154179.","DOI":"10.1136\/ard.2011.154179"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twentyeight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8. doi: 10.1002\/art.1780380107.","DOI":"10.1002\/art.1780380107"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. doi: 10.1093\/rheumatology\/keg072.","DOI":"10.1093\/rheumatology\/keg072"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53. doi: 10.1002\/art.1780261107.","DOI":"10.1002\/art.1780261107"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659-62. doi: 10.1001\/ jama.1949.02900430001001.","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"ref-18","unstructured":"Institute. NC. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. National Institutes and Health 2017; 2017."},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"Kurita N, Kamitani T, Wada O, Shintani A, Mizuno K. Disentangling associations between serum muscle biomarkers and sarcopenia in the presence of pain and inflammation among patients with osteoarthritis: The SPSS-OK study. J Clin Rheumatol 2021;27:56- 63. doi: 10.1097\/RHU.0000000000001156.","DOI":"10.1097\/RHU.0000000000001156"},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Pang L, Wang Z, Zhao ZL, Guo Q, Huang CW, Du JL, et al. Associations between estimated glomerular filtration rate and cardiac biomarkers. J Clin Lab Anal 2020;34:e23336. doi: 10.1002\/jcla.23336.","DOI":"10.1002\/jcla.23336"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017;13:234-43. doi: 10.1038\/nrrheum.2017.23.","DOI":"10.1038\/nrrheum.2017.23"}],"container-title":["Archives of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1424\/2540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1424\/2541","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1424\/2540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:01:13Z","timestamp":1761210073000},"score":1,"resource":{"primary":{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/view\/1424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9,30]]}},"URL":"https:\/\/doi.org\/10.46497\/archrheumatol.2024.10645","relation":{},"ISSN":["2618-6500"],"issn-type":[{"value":"2618-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}